Anitocabtagene Autoleucel

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes that are genetically modified ex vivo and transduced with a lentiviral vector to express a D-binding domain based chimeric antigen receptor (CAR) that specifically recognizes the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) that is fused to the intracellular signaling domains of 4-1BB (CD137) and the T-cell receptor signaling domain of CD3zeta (CD3z), with potential immunostimulating and antineoplastic activities. Upon administration, anitocabtagene autoleucel specifically recognizes and induces selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells. The use of a synthetic D-domain protein as the antigen binding domain may allow for increased CAR density on the T-cell surface, may reduce immunogenicity, may increase CAR cell surface stability, may improve CAR T-cell function and persistence, and may increase tumor cell killing.

**Synonyms:** - ANITOCABTAGENE AUTOLEUCEL - Anito-cel - Autologous Anti-BCMA D-domain CAR-T Cells CART-ddBCMA - CART-ddBCMA